 | • レポートコード：QFJ1-4247 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、血液がん遺伝子改変免疫療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（CAR T細胞療法、TCRT細胞療法）、用途別市場規模（急性リンパ性白血病、慢性リンパ性白血病、B細胞リンパ腫、多発性骨髄腫、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・血液がん遺伝子改変免疫療法の市場動向 ・企業の競争状況、市場シェア ・血液がん遺伝子改変免疫療法の種類別市場規模と予測2016-2027（CAR T細胞療法、TCRT細胞療法） ・血液がん遺伝子改変免疫療法の用途別市場規模と予測2016-2027（急性リンパ性白血病、慢性リンパ性白血病、B細胞リンパ腫、多発性骨髄腫、その他） ・血液がん遺伝子改変免疫療法の北米市場規模2016-2027（アメリカ、カナダ） ・血液がん遺伝子改変免疫療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・血液がん遺伝子改変免疫療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・血液がん遺伝子改変免疫療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・血液がん遺伝子改変免疫療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、Kite Pharma、Juno Therapeutics、Cellectis、Ziopharm Oncology、Celyad、Bluebird Bio、Bellicum Pharmaceuticals、Mustang Bio） ・結論 |
Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient’s own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
Market Analysis and Insights: Global Gene Modifying Immunotherapy for Blood Cancer Market
The global Gene Modifying Immunotherapy for Blood Cancer market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Modifying Immunotherapy for Blood Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Modifying Immunotherapy for Blood Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Modifying Immunotherapy for Blood Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Modifying Immunotherapy for Blood Cancer market.
Global Gene Modifying Immunotherapy for Blood Cancer Scope and Market Size
Gene Modifying Immunotherapy for Blood Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Modifying Immunotherapy for Blood Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
CAR T-cell Therapy
TCR T-cell Therapy
Segment by Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 CAR T-cell Therapy
1.2.3 TCR T-cell Therapy
1.3 Market by Application
1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2016-2027)
2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Share by Regions (2016-2021)
2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Regions (2022-2027)
2.3 Gene Modifying Immunotherapy for Blood Cancer Industry Dynamic
2.3.1 Gene Modifying Immunotherapy for Blood Cancer Market Trends
2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue
3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2016-2021)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2016-2021)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2020
3.5 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
3.6 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
3.7 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2016-2021)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2022-2027)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2016-2021)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2016-2027)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
6.2.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021)
6.2.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027)
6.2.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2027)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
6.3.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021)
6.3.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027)
6.3.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2027)
6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
6.4.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021)
6.4.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2016-2027)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
7.2.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021)
7.2.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027)
7.2.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2027)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
7.3.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021)
7.3.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027)
7.3.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2027)
7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
7.4.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021)
7.4.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size (2016-2027)
8.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
8.2.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
8.3.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region
8.4.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2016-2027)
9.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
9.2.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021)
9.2.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027)
9.2.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2027)
9.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
9.3.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021)
9.3.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027)
9.3.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2027)
9.4 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
9.4.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021)
9.4.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size (2016-2027)
10.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
10.2.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
10.3.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
10.4.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Details
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.2.5 Kite Pharma Recent Development
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Details
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.3.5 Juno Therapeutics Recent Development
11.4 Cellectis
11.4.1 Cellectis Company Details
11.4.2 Cellectis Business Overview
11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.4.5 Cellectis Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.5.5 Ziopharm Oncology Recent Development
11.6 Celyad
11.6.1 Celyad Company Details
11.6.2 Celyad Business Overview
11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.6.5 Celyad Recent Development
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Details
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.7.5 Bluebird Bio Recent Development
11.8 Bellicum Pharmaceuticals
11.8.1 Bellicum Pharmaceuticals Company Details
11.8.2 Bellicum Pharmaceuticals Business Overview
11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.8.5 Bellicum Pharmaceuticals Recent Development
11.9 Mustang Bio
11.9.1 Mustang Bio Company Details
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
11.9.5 Mustang Bio Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of CAR T-cell Therapy
Table 3. Key Players of TCR T-cell Therapy
Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2016-2021)
Table 8. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2022-2027)
Table 10. Gene Modifying Immunotherapy for Blood Cancer Market Trends
Table 11. Gene Modifying Immunotherapy for Blood Cancer Market Drivers
Table 12. Gene Modifying Immunotherapy for Blood Cancer Market Challenges
Table 13. Gene Modifying Immunotherapy for Blood Cancer Market Restraints
Table 14. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players (2016-2021)
Table 16. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2020)
Table 17. Ranking of Global Top Gene Modifying Immunotherapy for Blood Cancer Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
Table 21. Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2016-2021)
Table 25. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Application (2016-2021)
Table 29. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 61. Novartis Company Details
Table 62. Novartis Business Overview
Table 63. Novartis Gene Modifying Immunotherapy for Blood Cancer Product
Table 64. Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Kite Pharma Company Details
Table 67. Kite Pharma Business Overview
Table 68. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product
Table 69. Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 70. Kite Pharma Recent Development
Table 71. Juno Therapeutics Company Details
Table 72. Juno Therapeutics Business Overview
Table 73. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product
Table 74. Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 75. Juno Therapeutics Recent Development
Table 76. Cellectis Company Details
Table 77. Cellectis Business Overview
Table 78. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product
Table 79. Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 80. Cellectis Recent Development
Table 81. Ziopharm Oncology Company Details
Table 82. Ziopharm Oncology Business Overview
Table 83. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product
Table 84. Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 85. Ziopharm Oncology Recent Development
Table 86. Celyad Company Details
Table 87. Celyad Business Overview
Table 88. Celyad Gene Modifying Immunotherapy for Blood Cancer Product
Table 89. Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 90. Celyad Recent Development
Table 91. Bluebird Bio Company Details
Table 92. Bluebird Bio Business Overview
Table 93. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 94. Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 95. Bluebird Bio Recent Development
Table 96. Bellicum Pharmaceuticals Company Details
Table 97. Bellicum Pharmaceuticals Business Overview
Table 98. Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 99. Bellicum Pharmaceuticals Recent Development
Table 100. Mustang Bio Company Details
Table 101. Mustang Bio Business Overview
Table 102. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 103. Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021) & (US$ Million)
Table 104. Mustang Bio Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Type: 2020 VS 2027
Figure 2. CAR T-cell Therapy Features
Figure 3. TCR T-cell Therapy Features
Figure 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2020 VS 2027
Figure 5. Acute Lymphocytic Leukemia Case Studies
Figure 6. Chronic Lymphocytic Leukemia Case Studies
Figure 7. B Cell Lymphoma Case Studies
Figure 8. Multiple Myeloma Case Studies
Figure 9. Other Case Studies
Figure 10. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
Figure 11. Global Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions: 2020 VS 2027
Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2022-2027)
Figure 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players in 2020
Figure 16. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2020
Figure 18. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2016-2021)
Figure 19. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2022-2027)
Figure 20. North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2016-2027)
Figure 22. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2016-2027)
Figure 23. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2016-2027)
Figure 24. United States Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2016-2027)
Figure 28. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2016-2027)
Figure 29. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2016-2027)
Figure 30. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2016-2027)
Figure 40. China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2016-2027)
Figure 48. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2016-2027)
Figure 49. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2016-2027)
Figure 50. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2016-2027)
Figure 56. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 60. Kite Pharma Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 61. Juno Therapeutics Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 62. Cellectis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 63. Ziopharm Oncology Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 64. Celyad Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 65. Bluebird Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 66. Bellicum Pharmaceuticals Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 67. Mustang Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
世界のB細胞慢性リンパ性白血病治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global B-Cell Chronic Lymphocytic Leukemia Treatment Market The global B-Cell Chronic Lymphocytic Leukemia Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy…- B細胞慢性リンパ性白血病の治療のグローバル市場調査 2019年 The global B-Cell Chronic Lymphocytic Leukemia Treatment market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on B-Cell Chronic Lymphocytic Leukemia Treatment volume and value at global level, regional leve…
- 世界のT細胞急性リンパ芽球性白血病治療市場規模・現状・予測（2021年-2027年） T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia, with features similar to lymphoma. It affects white blood cells called T lymphocytes. Market Analysis and Insights: Global T-cell Acute Lymphoblastic Leukemia Treatment Market The global T-cell Acute Lymphoblastic…
- 世界の慢性リンパ性白血病（CLL）治療市場規模・現状・予測（2021年-2027年） Treatment options for chronic lymphocytic leukemia (CLL) vary greatly, depending on the person’s age, the disease risk group, and the reason for treating (for example, which symptoms it is causing). Market Analysis and Insights: Global Chronic Lymphocytic Leukemia (CLL) Treatment Market The global C…
- 世界の急性リンパ性/リンパ芽球性白血病（ALL）治療法市場規模・現状・予測（2021年-2027年） Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body. ALL develops in bone marrow and quickly invades other parts of the body including the liver, spleen, lymph …